ArticleJournal of inflammation research2025
N-Acetylcysteine as a Potential Immunomodulator in Tuberculosis: Evidence of IL-2 Elevation in a Pilot Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Aimed to investigate the potential of N-acetylcysteine (NAC) as an adjunctive immunomodulatory therapy to support the host immune response against Patients and Methods: A quasi-experimental study was conducted on the effect of NAC administration on IL-2 levels in patients newly diagnosed with pulmonary tuberculosis at Universitas Airlangga Teaching Hospital, Indonesia. Participants who met the inclusion criteria were subsequently divided into two groups: treatment group (received 600 mg every 12 hours of NAC therapy, n = 15) and control group (did not receive NAC therapy, n = 15). Enzyme-linked immunosorbent assay (ELISA) was used to analyze IL-2 levels in both groups, which were subsequently compared using statistical analysis. Results: Analysis of IL-2 levels before treatment with NAC revealed no significant difference between the treatment and control groups. The treatment group exhibited a significant increase in IL-2 levels after NAC administration (p=0.023). The median IL-2 level in the treatment group increased from 243.7 to 386.62 ng/L after two weeks of NAC administration, whereas in the control group, it decreased from 303.6 to 285.89 ng/L. The comparison test analysis of delta IL-2 levels also showed a significant difference between the treatment and control group (p = 0.025), with the median value of delta IL-2 levels in the treatment group being 147.0 ng/L and -24.7 ng/L in the control group. Conclusion: This preliminary study demonstrated that IL-2 levels significantly increased with NAC supplementation, suggesting an enhanced immune response and its potential as an adjunct to standard tuberculosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.